Preclinical COPD research with positive controls
We would like to introduce a positive control (Roflumilast) in a drug efficacy evaluation study using PPE-induced COPD model.
Our clients previously asked, “Do you have a positive control for COPD trials?” and we have now acquired the data and launched the product. The drug used as a positive control is roflumilast, a PDE-4 inhibitor.
Mean linear intercept by histological analysis of the lungs, the primary endpoint of the COPD model, was significantly lower in the roflumilast-treated group compared with the disease control group, confirming the protective effect of roflumilast on lung alveolar wall destruction.
The study summary at that time was as follows.
– Duration of treatment; 3 weeks (Day 0 to Day 21) from the same day of PPE administration.
– Group composition; Disease control group and roflumilast group
– Endpoint endpoints; Mean liner intercept
As the action of roflumilast has been shown to be reproducible, we have established roflumilast as a positive control in our study with the COPD model.
Why not use this positive control to carry out a drug efficacy evaluation study of your test substance?
